Trial Profile

A Phase 1/2 of Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of TPX-0022 in Adult Subjects With Locally Advanced or Metastatic NSCLC, Gastric Cancer, or Solid Tumors Harboring Genetic Alterations in MET

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 27 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elzovantinib (Primary)
Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Glioblastoma; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
Focus Adverse reactions; First in man
Acronyms SHIELD-1
Sponsors Turning Point Therapeutics

20 Dec 2024 Planned End Date changed from 2 Mar 2025 to 31 Mar 2026.
16 Nov 2023 Planned End Date changed from 30 Nov 2023 to 2 Mar 2025.
16 Nov 2023 Planned primary completion date changed from 30 Nov 2023 to 2 Mar 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com